An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralizing antibodies. These can eliminate the intruders and have great potential to be used for prevention and treatment of SARS-CoV-2 infection.
A team of researchers led by Prof. Florian Klein (Director of the Institute for Virology at the Cologne University Hospital and affiliated with the Center for Molecular Medicine Cologne) and the German Center for Infection Research (DZIF) has further elucidated how these antibodies develop and has isolated potent SARS-CoV-2 neutralizing antibodies. Together with Boehringer Ingelheim, these antibodies are currently being further characterized and developed. It is expected that they will enter the stage of clinical development later this year.
The results were published on July 07, 2020 in the journal Cell with the following title "Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients" https://www.cell.com/cell/fulltext/S0092-8674(20)30821-7
“Our goal was to better understand the immune response to SARS-CoV-2 and to identify highly potent antibodies that could be used to prevent and treat COVID-19,” explained Prof. Klein, Director of the Institute for Virology at the Cologne University Hospital and Principal Investigator at the DZIF. “We assume that such antibodies are effective for several weeks and may protect against COVID-19 during this period,” added Dr. Christoph Kreer, who conducted the work together with Dr. Matthias Zehner in Cologne.
In close collaboration with scientists from Marburg, Frankfurt, Munich, Tübingen and Israel, the researchers investigated the SARS-CoV-2 antibody response in twelve individuals recovered from COVID-19. They examined more than 4000 SARS-CoV-2-specific B cells on a single cell level and were able to partly decode the humoral immune response to SARS-CoV-2. They reconstructed 255 antibodies in the laboratory, which were examined by Prof. Stephan Becker’s laboratory in Marburg for their ability to neutralize the novel coronavirus SARS-CoV-2. In total, 28 neutralizing antibodies were found.
“Interestingly, many antibodies showed only a small number of mutations. This means that only minor changes were necessary to effectively recognize and neutralize the virus” says Dr. Zehner. In fact, in blood samples collected before the pandemic, the scientists found B cells carrying similar antibody characteristics to those of SARS-CoV-2 neutralizing antibodies. This may suggest that SARS-CoV-2 antibodies can be readily formed and that an active vaccine may provide rapid protection.
The antibodies have been developed for protecting against and treating COVID-19. In addition, these antibodies could be used for ‘post-exposure prophylaxis'. Here antibodies would be applied after contact with an infected individual.
“This form of intervention could be of particular interest for stopping localised outbreaks and for preventing disease progression in people at risk”, said Prof. Klein. The scientists expect that first clinical trials will be performed at the end of 2020.
Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients
Christoph Kreer, Matthias Zehner, Timm Weber, Meryem S. Ercanoglu, Lutz Gieselmann, Cornelius Rohde, Sandro Halwe, Michael Korenkov, Philipp Schommers, Kanika Vanshylla, Veronica Di Cristanziano, Hanna Janicki, Reinhild Brinker, Artem Ashurov, Verena Krähling, Alexandra Kupke, Hadas Cohen-Dvashi, Manuel Koch, Jan Mathis Eckert, Simone Lederer, Nico Pfeifer, Timo Wolf, Maria J.G.T. Vehreschild, Clemens Wendtner, Ron Diskin, Henning Gruell, Stephan Becker and Florian Klein
Open Access Published: July 07, 2020DOI: https://doi.org/10.1016/j.cell.2020.06.044
Prof. Dr. Florian Klein
Director - Institute for Virology: http://virologie.uk-koeln.de/
Klein Lab - Laboratory of Experimental Immunology: https://klein-lab.de/
associated CMMC Research Group: https://www.cmmc-uni-koeln.de/research/research-areas-projects/research-area-b/florian-klein-assoc-rg
Press Release from the German Center for Infectious Research (DZIF) modified by Dr. Debora Grosskopf-Kroiher - Center for Molecular Medicine Cologne - debora.grosskopf-kroiher[at]uni-koeln.de
Original Press Release: https://www.dzif.de/en/neutralising-antibodies-battle-against-covid-19